Evidence map›Paper›PMID 30664714›Full record

ArticleEuropean journal of human genetics : EJHG2019

Spatially clustering de novo variants in CYFIP2, encoding the cytoplasmic FMRP interacting protein 2, cause intellectual disability and seizures.

Markus Zweier, Anaïs Begemann, Kirsty McWalter, Megan T Cho, Lucia Abela, Siddharth Banka, Bettina Behring, Andrea Berger, Chester W Brown, Maryline Carneiro and 29 more

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Expanding the Phenotype ofAnnals of the Child Neurology Society · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Case Report: An adult withFrontiers in psychiatry · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 18 institutions in 8 countries.

Markus ZweierInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Anaïs BegemannInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.ORCID 0000-0001-6762-0819
Kirsty McWalterGeneDx, Gaithersburg, MD, USA.
Megan T ChoGeneDx, Gaithersburg, MD, USA.
Lucia AbelaRadiz-Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Zurich, Switzerland.
Siddharth BankaManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
Bettina BehringDepartment of Pediatrics, Klinikum Nuremberg, Nuremberg, Germany.
Andrea BergerDepartment of Neuropediatrics, Klinikum Weiden, Kliniken Nordoberpfalz AG, Weiden, Germany.
Chester W BrownLe Bonheur Children's Hospital, Memphis, TN, USA.
Maryline CarneiroDepartment of Neuropediatrics, Lyon University Hospital, Lyon, France.
Jiani ChenUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Gregory M CooperHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Deciphering Developmental Disorders (DDD) Study
Candice R FinnilaHudsonAlpha Institute for Biotechnology, Huntsville, AL, USA.
Maria J Guillen SacotoGeneDx, Gaithersburg, MD, USA.
Alex HendersonNorthern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 3BZ, UK.
Ulrike HüffmeierInstitute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Pascal JosetInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Bronwyn KerrManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
Gaetan LescaDepartment of Medical Genetics, Lyon University Hospital, Lyon, France.
Gloria S LeszinskiInstitute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
John Henry McDermottManchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK.
Meira R MeltzerChildren's National Health System, Washington, DC, USA.
Kristin G MonaghanGeneDx, Gaithersburg, MD, USA.
Roya MostafaviLe Bonheur Children's Hospital, Memphis, TN, USA.
Katrin ÕunapDepartment of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Barbara PleckoRadiz-Rare Disease Initiative Zurich, Clinical Research Priority Program for Rare Diseases, University of Zurich, Zurich, Switzerland.
Zöe PowisAmbry Genetics, Aliso Viejo, CA, USA.ORCID 0000-0002-1347-4358
Gabriela PurcarinUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Tiia ReimandDepartment of Clinical Genetics, Institute of Clinical Medicine, University of Tartu, Tartu, Estonia.
Korbinian M RiedhammerInstitute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
John M SchreiberChildren's National Health System, Washington, DC, USA.
Deepa SirsiDepartment of Pediatrics, Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Klaas J WierengaUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Monica H WojcikBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Sorina M PapucInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Katharina SteindlInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland.
Heinrich StichtInstitute of Biochemistry, Emil-Fischer Center, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Anita RauchInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich, Switzerland. anita.rauch@medgen.uzh.ch.ORCID 0000-0003-2930-3163
University of Zurich · CHChildren's National · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DETartu University Hospital · EEHudsonAlpha Institute for Biotechnology · USBroad Institute · USUniversité Claude Bernard Lyon 1 · FRAmbry Genetics (United States) · USHospices Civils de Lyon · FRKlinikum Weiden · DELe Bonheur Children's Hospital · USMedical University of Graz · ATNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNuremberg Hospital · DETUM Klinikum · DEUniversity of Manchester · GBUniversity of Oklahoma Health Sciences Center · USUniversity of Tennessee Health Science Center · US

Funding

Joint Center for Mendelian GenomicsUM1HG008900 · NHGRI · BROAD INSTITUTE, INC. · PI O'DONNELL-LURIA, ANNE, REHM, HEIDI L · 2016 to 2020
$16.5M
TRAINING GRANT IN GENETICST32GM007748 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Anne O'Donnell-Luria, Louise Wilkins-Haug · 1985 to 2026
$12.0M
NHGRI NIH HHS UM1 HG008900NIGMS NIH HHS T32 GM007748Wellcome Trust
6 · The paper itself

Abstract

CYFIP2, encoding the evolutionary highly conserved cytoplasmic FMRP interacting protein 2, has previously been proposed as a candidate gene for intellectual disability and autism because of its important role linking FMRP-dependent transcription regulation and actin polymerization via the WAVE regulatory complex (WRC). Recently, de novo variants affecting the amino acid p.Arg87 of CYFIP2 were reported in four individuals with epileptic encephalopathy. We here report 12 independent patients harboring a variety of de novo variants in CYFIP2 broadening the molecular and clinical spectrum of a novel CYFIP2-related neurodevelopmental disorder. Using trio whole-exome or -genome sequencing, we identified 12 independent patients carrying a total of eight distinct de novo variants in CYFIP2 with a shared phenotype of intellectual disability, seizures, and muscular hypotonia. We detected seven different missense variants, of which two occurred recurrently (p.(Arg87Cys) and p.(Ile664Met)), and a splice donor variant in the last intron for which we showed exon skipping in the transcript. The latter is expected to escape nonsense-mediated mRNA decay resulting in a truncated protein. Despite the large spacing in the primary structure, the variants spatially cluster in the tertiary structure and are all predicted to weaken the interaction with WAVE1 or NCKAP1 of the actin polymerization regulating WRC-complex. Preliminary genotype-phenotype correlation indicates a profound phenotype in p.Arg87 substitutions and a more variable phenotype in other alterations. This study evidenced a variety of de novo variants in CYFIP2 as a novel cause of mostly severe intellectual disability with seizures and muscular hypotonia.

Indexed as

Adaptor Proteins, Signal TransducingChildChild, PreschoolCytoplasmFaciesFemaleHumansInfantIntellectual DisabilityMaleModels, MolecularMutationSeizuresAdaptor Proteins, Signal TransducingCYFIP2 protein, human

Identifiers

PMID30664714
PMCPMC6461771
OpenAlexW2911076095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.